- Conditions
- Sickle Cell Disease, Hemolytic Anemia
- Interventions
- Mitapivat
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 789
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Nitrous oxide 50%
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hematologic Diseases, Anemia, Sickle Cell
- Interventions
- Intravenous Ketorolac, Ibuprofen
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- GMI-1070
- Drug
- Lead sponsor
- GlycoMimetics Incorporated
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Oakland, California • Sacramento, California • Durham, North Carolina
- Conditions
- Healthy Volunteers, Anemia, Sickle Cell
- Interventions
- AG-946, AG-946 Matched Placebo
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- La Jolla, California • Boston, Massachusetts • New York, New York + 4 more
- Conditions
- Positive FIT or Stool DNA Testing Follow up
- Interventions
- Patient navigator
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Sickle Cell Disease & Thalassemia
- Interventions
- NiCord
- Drug
- Lead sponsor
- Gamida Cell ltd
- Industry
- Eligibility
- 2 Years to 45 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 3
- States / cities
- New York, New York • Durham, North Carolina • Houston, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Motixafortide, Natalizumab, Leukapheresis
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Nocturnal Enuresis, Anemia, Sickle Cell
- Interventions
- Desmopressin
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
- Interventions
- HQK-1001, Placebo
- Drug
- Lead sponsor
- HemaQuest Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 11
- States / cities
- Mobile, Alabama • Oakland, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Anemia, Sickle Cell
- Interventions
- Arginine, Placebo
- Drug
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 17
- States / cities
- Oakland, California • San Francisco, California • Denver, Colorado + 10 more
- Conditions
- Sleep Apnea, SCI/D, Hypercapnia
- Interventions
- Hypercapnia treatment
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Acute Kidney Injury, Hepatorenal Syndrome
- Interventions
- Selective Cytopheretic Device
- Device
- Lead sponsor
- Lenar Yessayan
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Sickle Cell Disease
- Interventions
- SelG1, Placebo
- Drug
- Lead sponsor
- Reprixys Pharmaceutical Corporation
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more
- Conditions
- Sickle Cell Disease, Beta Thalassemia-Major
- Interventions
- alemtuzumab (Campath IH), Fludarabine, Melphalan, Cyclosporine, Mycophenolate mofetil, Tacrolimus, Hematopoietic Stem Cell Transplantation
- Drug · Biological
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- Novartis
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,665 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Sickle Cell Disease
- Interventions
- Voxelotor Oral Tablet
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 30 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • The Bronx, New York
- Conditions
- Sickle Cell Anemia, Children, Only
- Interventions
- Hydroxyurea SDM Toolkit, Clinician Pocket Guide
- Behavioral
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Month to 5 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 8 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
- Interventions
- Inclacumab, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
- Conditions
- Cognitive Impairment, Dementia
- Interventions
- No interventions
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 1,892 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Sacramento, California • San Francisco, California + 12 more
- Conditions
- Sickle Cell Disease
- Interventions
- Heart Rate Variability Biofeedback
- Behavioral
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Sickle Cell Disease
- Interventions
- bb1111
- Genetic
- Lead sponsor
- Genetix Biotherapeutics Inc.
- Industry
- Eligibility
- 2 Years to 50 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
- Conditions
- Sickle Cell Disease (SCD)
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 3 Years to 20 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Wilmington, Delaware • Washington D.C., District of Columbia + 19 more